{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T13:48:17Z","timestamp":1648993697970},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/gme.0b013e31829c12e8","type":"journal-article","created":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T12:19:04Z","timestamp":1377001144000},"page":"236-242","source":"Crossref","is-referenced-by-count":3,"title":["Population pharmacokinetic\/pharmacodynamic evaluation of low-dose drospirenone with 17\u03b2-estradiol in postmenopausal women with moderate to severe vasomotor symptoms"],"prefix":"10.1097","volume":"21","author":[{"given":"Gabriele","family":"Sutter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schmelter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Gude","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Schaefers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Gerlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Archer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210211","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/01.gme.0000177318.24005.b1","article-title":"Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.","volume":"12","author":"Archer","year":"2005","journal-title":"Menopause"},{"key":"R2-8-20210211","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/13697130410001713698","article-title":"Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens.","volume":"7","author":"Schurmann","year":"2004","journal-title":"Climacteric"},{"key":"R3-8-20210211","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13697130310001651535","article-title":"Safety and efficacy of drospirenone used in a continuous combination with 17-estradiol for prevention of postmenopausal osteoporosis.","volume":"7","author":"Warming","year":"2004","journal-title":"Climacteric"},{"key":"R4-8-20210211","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(00)00133-5","article-title":"Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.","volume":"62","author":"Krattenmacher","year":"2000","journal-title":"Contraception"},{"issue":"suppl 3","key":"R5-8-20210211","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/13697130500330382","article-title":"Pharmacology of different progestogens: the special case of drospirenone.","volume":"8","author":"Sitruk-Ware","year":"2005","journal-title":"Climacteric"},{"key":"R6-8-20210211","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0010-7824(96)00195-3","article-title":"The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential.","volume":"54","author":"Fuhrmann","year":"1996","journal-title":"Contraception"},{"key":"R7-8-20210211","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1749-6632.1995.tb31386.x","article-title":"Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.","volume":"761","author":"Muhn","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"R8-8-20210211","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.104.501502","article-title":"Antihypertensive effects of drospirenone with 17-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension.","volume":"112","author":"White","year":"2005","journal-title":"Circulation"},{"key":"R9-8-20210211","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.HYP.0000232179.60442.84","article-title":"Effects of a new hormone therapy, drospirenone and 17--estradiol, in postmenopausal women with hypertension.","volume":"48","author":"White","year":"2006","journal-title":"Hypertension"},{"key":"R10-8-20210211","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/GME.0b013e31829c1431","article-title":"A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.","volume":"21","author":"Archer","year":"2014","journal-title":"Menopause"},{"key":"R11-8-20210211","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/1568016052773270","article-title":"Smoking, estradiol metabolism and hormone replacement therapy.","volume":"3","author":"Mueck","year":"2005","journal-title":"Curr Med Chem Cardiovasc Hematol Agents"},{"key":"R12-8-20210211","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/gme.0b013e3181cb49e9","article-title":"The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin levels in healthy postmenopausal women.","volume":"17","author":"Edlefsen","year":"2010","journal-title":"Menopause"},{"key":"R15-8-20210211","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.maturitas.2010.01.019","article-title":"Interaction between menopausal status and obesity in affecting breast cancer risk.","volume":"66","author":"Rose","year":"2010","journal-title":"Maturitas"},{"key":"R16-8-20210211","first-page":"8623","article-title":"Methylation of cytochrome P4501A1 promoter in the lung is associated with tobacco smoking.","volume":"63","author":"Anttila","year":"2003","journal-title":"Cancer Res"},{"key":"R17-8-20210211","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1158\/0008-5472.CAN-04-3543","article-title":"Association of CYP1A1 polymorphisms with differential metabolic activation of 17-estradiol and estrone.","volume":"65","author":"Kisselev","year":"2005","journal-title":"Cancer Res"},{"key":"R18-8-20210211","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0015-0282(01)01791-5","article-title":"Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.","volume":"75","author":"Utian","year":"2001","journal-title":"Fertil Steril"},{"key":"R19-8-20210211","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/jama.1980.03310130021021","article-title":"Oral medroxyprogesterone in the treatment of postmenopausal symptoms.","volume":"244","author":"Schiff","year":"1980","journal-title":"JAMA"},{"key":"R20-8-20210211","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/gme.0b013e318247f07a","article-title":"Oral micronized progesterone for vasomotor symptomsa placebo-controlled randomized trial in healthy postmenopausal women.","volume":"19","author":"Hitchcock","year":"2012","journal-title":"Menopause"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GME.0b013e31829c12e8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:42:51Z","timestamp":1620952971000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042192-201403000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e31829c12e8","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}